Insider · CIK 0002083297
Peter Stazzone
Files at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). First filing -, latest -.
In brief
Peter Stazzone files SEC Form 4 as CFO at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Peter Stazzone has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 100,000 | Jul 2, 2026 |
| Apr 15, 2026 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Common Stock | +50,000 | - | - | 50,000 | Apr 17, 2026 |
| Apr 15, 2026 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | DDisposition to issuer Options to Purchase Common Stockderivative | -50,000 | - | - | 0 | Apr 17, 2026 |
| Sep 1, 2025 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Options to Purchase Common Stockderivative | +50,000 | $0.00 | $0 | 50,000 | Sep 4, 2025 |
Questions about Peter Stazzone
Answered from the filings on this page, as of the latest one.
Is Peter Stazzone buying or selling?
Peter Stazzone has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Peter Stazzone's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Peter Stazzone has 0.
Where does Peter Stazzone file Form 4?
Peter Stazzone has filed Form 4 at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.